cancers in indonesia, 2012 - world cancer congress€¦ · siklofosfamid . sisplatin . sitarabin ....
TRANSCRIPT
Cancers in Indonesia, 2012 Male Female Total
Number of population 2012 (000) 122.,012 122,756 244,769
Cancer incidence (000) 138.8 160.8 299.7 Morbidity risks of cancer before age 75 years [%] 14.4 13.8 14.0
Mortality caused by cancers (000) 102.7 91.8 194.5
Mortality risk from cancer before 75 years of age [%] 11.0 8.6 9.7
Cancer prevalence on adult (000) 234.9 409.7 644.6
Total cancer prevalence [per 100.000 population] 263.6 449.8 357.7
: Ferlay, et al. (2013) dan Bray, et al. (2013)
28/11/2016 authors' perspectives 2
+ 3,200 miles
Indonesia – Pop 257 million GDP/Capita 2015, US$ + 3.400
28/11/2016 authors' perspectives 3
How to reach cancer patients across country?
5,000 KM
Outline
1. ACTION Study: Household Burden of cancer patients
2. The Universal Health Coverage 3. Current Prospects and Achievements on
Cancer Treatments 4. The Prospects and Challenges
28/11/2016 authors' perspectives 4
The ACTION • It stands for the ASEAN CosT In ONcology, a study
by the George Institute, Sydney. Funded by Roche Asia Pacific 10.000 new cases in 8 Countries
• Data collected in 2012-2014. Each new case was observed for 12 months after diagnosis
• In Indonesia, ACTION involved 2.335 cases from 12 centers (hospital)
• Participation was voluntary, difficult and took time
28/11/2016 authors' perspectives 5
Flow of Data Collection, 2012-2014
28/11/2016 authors' perspectives 6
Very difficult to follow cancer patients for 12 months without insurance coverage
Distribution of Cancer Stages at the Diagnosis ACTION Indonesia
I 7%
II 27%
III 36%
IV 30%
28/11/2016 authors' perspectives 9
Catastrophic Expenditures by Type of Hospitals, % Patients. ACTION Indonesia
0
20
40
60
80
100
120
Private Public
% patients
28/11/2016 authors' perspectives 12
Percent Family Complaining Financial Hardship, ACTION Indonesia
50
52
54
56
58
60
62
64
66
at Diagnosis 12 Mo later
%
28/11/2016 authors' perspectives 13
Health Care Refrom was Started 2014
28/11/2016 authors' perspectives 14
28/11/2016 authors' perspectives 15
The Following Drugs are Covered under the Ina-Medicare
Asparaginase Bevasizumab Bleomisin busulfan Dakarbazin Daktinomisin Daunorubisin Doksorubisin Dosetaksel Epirubisin Erlotinib Etoposid Fludarabin Flourourasil Gefitinib
Gemsitabin hidroksi urea Idarubisin Ifosfamid imatinib mesilat Irinotekan Kapesitabin Karboplatin Klorambusil Lapatinib Melfalan Merkaptopurin Metotreksat Mitomisin Nilotimid
oktreotid LAR Oksaliplatin Paklitaksel Rituksimab Setuksimab Siklofosfamid Sisplatin Sitarabin Temozolamid trastuzumab Vinblastin Vinkristin Vinorelbin
28/11/2016 authors' perspectives 17
Four Highest Claim Costs of the JKN, the Indonesian UHC
28/11/2016 authors' perspectives 18
The Prospects and Challenges -1
• Cancer patients will continue to have better access and less household burdens in receiving cancer treatments
• Health care providers and oncologists have better chances to enhance treatments and control of cancer patients
• Pharmaceutical and medical technology companies have a better position than before in supplying cancer control and treatments
28/11/2016 authors' perspectives 24
• Cancer patients in distant to limited number of cancer centers/hospitals have less access due to transportation and other non-medical costs
• Increasing cases covered by the JKN invites concerns on claim costs of the very limited resources of the first implementation of JKN
• Shortage of oncologists are not being met in a short period • Many other challenges are faced by the Indonesian UHC. • Studies and research on how to ensure adequacy and equity
of cancer control, including screening/ early diagnosis, are among the top priority for the coming years
28/11/2016 authors' perspectives 25
The Prospects and Challenges -2
The Borobudur temple, built in the 9th century, was constructed for long time; it last long!!! So we expect the INA-Medicare will do
28/11/2016 authors' perspectives 26
The Indonesian UHC have started and have benefitted cancer patients. However, huge challenges ahead in the wide and scattered population in
more than 5,000 inhabited islands
Disclaimer • The ASEAN Study (ACTION) was funded by
Roche Asia Pacific through the George Institute, Sydney
• The data collection in Indonesia was funded by non-product related grant by Roche Indonesia
• The claim data were provided by the BPJS Kesehatan, the National Health Insurance Corporation
28/11/2016 authors' perspectives 27